Laura Niklason is the founder of Humacyte. Humacyte has raised $245M in total funding. Latest round: IPO. Based in Durham, United States.
Laura Niklason, M.D., Ph.D., is the founder, President, and CEO of Humacyte, a clinical-stage biotechnology company. She assumed the CEO role in 2020 and led the company's transition to public markets via a SPAC reverse merger in August 2021, raising $245 million and valuing the company at approximately $1.1 billion. She oversees the commercial-scale manufacturing of universally implantable bioengineered human tissues.
Full founder directory · Investor directory · Company funding database · Fundraising library